Early-Stage Detection of Hepatocellular Carcinoma: The Oncoguard™ Liver Solution

Roche test could lead to early identification of infections.

There is no vaccine against the hepatitis C virus. A subscription-like payment model may help overcome some of the cost issues posed by direct-acting antivirals.

If approved, elafibranor would be a second-line treatment for patients with primary biliary cholangitis. The Prescription Drug User Fee Act action date is June 10, 2024.

The authors found that patients who received DAA treatment had a five-year survival rate of 47.2% compared with 35.2% for untreated patients.

Researchers from the Centers for Disease Control and Prevention identified 315 deaths from hepatitis A.

In 2019, the worldwide burden of HCV exceeded 58 million people, with 14.9 million infections occurring in women aged 15 to 49 years.